Aller au contenu principal
xMedica

NCT07919678ClinicalTrials.gov

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of…

Phase 3656 participants recherchés40 sites2 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 10 days after the recorded start)First posted 2026-11-05; recorded start 2026-10-26
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 635 other studies in this databaseCounted from the lead sponsor named in the record (Pfizer)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 3 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 40 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 656 participants (target), run at 40 sites, across 2 countries.

How this score is built
  • Enrolment28/40

    656 participants (target)

  • Site count19/25

    40 sites

  • Country count7/15

    2 countries

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale10/10

    Pfizer has led 630 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.

Affections

  • Obesity
  • Overweight
  • Osteoarthritis of the Knee

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * Adults 18 years of age or older, or the minimum age of consent according to local regulations. * Body mass index of at least 27 kg/m² at Screening. * Currently meets American College of Rheumatology (ACR) Criteria for knee OA. * Pain due to knee OA. * Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3. * Willingness to complete the required analgesic washout. * History of at least 1 self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria * Self-reported body weight increase or decrease greater than 5% within 90 days before Screening. * History of diabetes or Screening laboratory findings indicative of diabetes. * Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease. * Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. * Significant active or unstable psychiatric disorder. * Condition or knee disorder that could confound assessment of target-knee pain. * Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study. * Recent use of weight-loss medication, any glucose-lowering therapy, or other protocol-prohibited treatment. * Prior participation in a berobenatide clinical trial with receipt of active treatment or placebo. * Hypersensitivity to a drug with glucagon-like peptide-1 receptor activity, including berobenatide, or any excipient.

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement656 participants recherchés

Promoteur et collaborateurs

  • Pfizer Promoteur

Groupes et interventions

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive placebo as subcutaneous injection

  • Arm 1: Berobenatide Once MonthlyEXPERIMENTAL

    Participants will receive berobenatide by subcutaneous injection.

  • Arm 2: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

  • Arm 3: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

Interventions

  • Médicament Berobenatide

    Subcutaneous Injection

  • Autre Placebo

    Subcutaneous Injection

Critères de jugement

  1. Critère de jugement principal

    Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score

    Délai Baseline and Week 52

  2. Critère de jugement secondaire

    Percent change from baseline in Body Weight

    Délai Baseline and Week 52

  3. Critère de jugement secondaire

    Change From Baseline in High-Sensitivity C-Reactive Protein

    Délai Baseline and Week 52

  4. Critère de jugement secondaire

    Change from baseline in WOMAC Physical Function Subscale score

    Délai Baseline and Week 52

  5. Critère de jugement secondaire

    Percentage of participants with ≥50% reduction in the WOMAC pain subscale score

    Délai Baseline and Week 52

  6. Critère de jugement secondaire

    Percentage of participants with ≥30% reduction in the WOMAC pain subscale score

    Délai Baseline and Week 52

  7. Critère de jugement secondaire

    Proportion of participants with utilization of protocol specified pain medication during the washout period

    Délai Baseline and Week 52

  8. Critère de jugement secondaire

    Amount of protocol specified pain medication during the washout period

    Délai Baseline and Week 52

  9. Critère de jugement secondaire

    Change from baseline in WOMAC stiffness score

    Délai Baseline and Week 52

  10. Critère de jugement secondaire

    Change from baseline in WOMAC total score

    Délai Baseline and Week 52

  11. Critère de jugement secondaire

    Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score

    Délai Baseline and Week 52

  12. Critère de jugement secondaire

    Proportion of participants meeting OMERACT-OARSI

    Délai Baseline and Week 52

  13. Critère de jugement secondaire

    Change from baseline in Average Pain Intensity-Numerical Rating Score

    Délai Baseline and Week 52

  14. Critère de jugement secondaire

    Change from baseline in Worst Pain Intensity -Numerical Rating Score

    Délai Baseline and Week 52

  15. Critère de jugement secondaire

    Change from baseline in SF-36 domain scales and component summary scales

    Délai Baseline and Week 52

  16. Critère de jugement secondaire

    Change from baseline in Body Weight

    Délai Baseline and Week 52

  17. Critère de jugement secondaire

    Change from Baseline in Body Mass Index

    Délai Baseline and Week 52

  18. Critère de jugement secondaire

    Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Délai Baseline and Week 52

  19. Critère de jugement secondaire

    Number of Participants with Serious Adverse Events (SAE)

    Délai Baseline and Week 52

  20. Critère de jugement secondaire

    Number of Participants with AE leading to permanent discontinuation from study intervention or study

    Délai Baseline and Week 52

  21. Critère de jugement secondaire

    Number of Participants with Adverse Events of Special Interest (AESI)

    Délai Baseline and Week 52

  22. Critère de jugement secondaire

    Number of Participants with Clinical laboratory abnormalities

    Délai Baseline and Week 52

  23. Critère de jugement secondaire

    Change from baseline in timed walking distance at Week 52

    Délai Baseline and Week 52

  24. Critère de jugement secondaire

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function

    Délai Baseline and Week 52

  25. Critère de jugement secondaire

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain

    Délai Baseline and Week 52

  26. Critère de jugement secondaire

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function

    Délai Baseline and Week 52

  27. Critère de jugement secondaire

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain

    Délai Baseline and Week 52

  28. Critère de jugement secondaire

    Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score

    Délai Baseline and Week 52

  29. Critère de jugement secondaire

    Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score

    Délai Baseline and Week 52

  30. Critère de jugement secondaire

    Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score

    Délai Baseline and Week 52

  31. Critère de jugement secondaire

    Change From Baseline in WPAI:GH Work productivity loss score

    Délai Baseline and Week 52

  32. Critère de jugement secondaire

    Change From Baseline in WPAI:GH Activity impairment score

    Délai Baseline and Week 52

  33. Critère de jugement secondaire

    Change From Baseline in Systolic Blood Pressure (SBP)

    Délai Baseline and Week 52

  34. Critère de jugement secondaire

    Change From Baseline in Diastolic Blood Pressure (DBP)

    Délai Baseline and Week 52

  35. Critère de jugement secondaire

    Change From Baseline in Total Cholesterol

    Délai Baseline and Week 52

  36. Critère de jugement secondaire

    Change From Baseline in High-density lipoprotein cholesterol (HDL-C)

    Délai Baseline and Week 52

  37. Critère de jugement secondaire

    Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)

    Délai Baseline and Week 52

  38. Critère de jugement secondaire

    Change from baseline in Non-HDL Cholesterol

    Délai Baseline and Week 52

  39. Critère de jugement secondaire

    Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol

    Délai Baseline and Week 52

  40. Critère de jugement secondaire

    Change from baseline in Triglycerides

    Délai Baseline and Week 52

Dates

Dates
Date de début26 octobre 2026 (réelle)
Achèvement principal22 août 2028 (estimée)
Achèvement10 octobre 2028 (estimée)
Première publication5 novembre 2026 (réelle)
Dernière mise à jour5 novembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisoctobre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

7 sites sont en recrutement

Canada

Canada
ÉtablissementVilleÉtat ou régionStatut
Bluewater Clinical Research Group Inc.SarniaOntarioPas encore en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Albuquerque Clinical Trials, Inc.AlbuquerqueNew MexicoPas encore en recrutement
Charlottesville Medical Research Center, LLCCharlottesvilleVirginiaPas encore en recrutement
Northwestern University Feinberg School Of MedicineChicagoIllinoisPas encore en recrutement
Great Lakes Clinical Trials, LLC dba Flourish ResearchChicagoIllinoisPas encore en recrutement
Northwestern MedicineChicagoIllinoisPas encore en recrutement
Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG)ChicagoIllinoisPas encore en recrutement
Northwestern Memorial Hospital, Investigational Drug ServiceChicagoIllinoisPas encore en recrutement
Clinical Research of West Florida, Inc.ClearwaterFloridaPas encore en recrutement
Skylight Health ResearchColorado SpringsColoradoPas encore en recrutement
Mercy Family ClinicDallasTexasPas encore en recrutement
Universal Axon Clinical Research LLCDoralFloridaEn recrutement
Altoona Center For Clinical ResearchDuncansvillePennsylvaniaEn recrutement
Headlands Research California, LLCEscondidoCaliforniaPas encore en recrutement
Profound Research LLCFarmington HillsMichiganEn recrutement
Cedar Health ResearchFort WorthTexasPas encore en recrutement
Novant Health Granite Quarry Internal Medicine (knee x-ray)Granite QuarryNorth CarolinaPas encore en recrutement
BRCR Global LouisianaGretnaLouisianaPas encore en recrutement
JCCT-JUNO NW HoustonHoustonTexasPas encore en recrutement
Westside Center for Clinical ResearchJacksonvilleFloridaPas encore en recrutement
Activian Clinical ResearchKingwoodTexasPas encore en recrutement
Renstar Medical ResearchLady LakeFloridaPas encore en recrutement
Monroe Biomedical ResearchMonroeNorth CarolinaEn recrutement
AMR ClinicalNormanOklahomaPas encore en recrutement
Renstar Medical ResearchOcalaFloridaPas encore en recrutement
Prospective Research Innovations Inc.Rancho CucamongaCaliforniaPas encore en recrutement
Accellacare - SalisburySalisburyNorth CarolinaPas encore en recrutement
Consano Clinical Research, LLCShavano ParkTexasPas encore en recrutement
Revive Research Institute, Inc.Sterling HeightsMichiganEn recrutement
Clinical Research AtlantaStockbridgeGeorgiaPas encore en recrutement
Clinical Research of West Florida, Inc.TampaFloridaPas encore en recrutement
AMR ClinicalTempeArizonaPas encore en recrutement
DM Clinical ResearchTomballTexasPas encore en recrutement
Solace Clinical ResearchTustinCaliforniaPas encore en recrutement
Velocity Clinical Research, WacoWacoTexasPas encore en recrutement
Elevate Clinical ResearchWichitaKansasPas encore en recrutement
Delaney RadiologistWilmingtonNorth CarolinaEn recrutement
AccellacareWilmingtonNorth CarolinaEn recrutement
North Georgia Internal MedicineWoodstockGeorgiaPas encore en recrutement
North Georgia Clinical Research, LLCWoodstockGeorgiaPas encore en recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

Aucun changement n'a été enregistré depuis que nous avons intégré cette fiche pour la première fois.

Un changement est enregistré chaque fois que le promoteur met à jour la fiche du registre. Le statut, les dates, le recrutement et les sites apparaissent ici au fur et à mesure de leur évolution.